Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 101 of 116

  1. OMP-131R10

    Mereo BioPharma Group plc

    Advanced Relapsed Tumors

    phase 1 small molecule completed

    1 trial

  2. OMP-18R5

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 mab completed

    1 trial

  3. OMP-21M18

    Mereo BioPharma Group plc

    Colorectal Cancer

    phase 1 small molecule completed

    1 trial

  4. OMP-21M18

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  5. OMP-305B83

    Mereo BioPharma Group plc

    Metastatic Colorectal Cancer

    phase 1 small molecule terminated

    1 trial

  6. OMP-305B83

    Mereo BioPharma Group plc

    Advanced Solid Tumor Malignancies

    phase 1 small molecule completed

    1 trial

  7. OMP-305B83

    Mereo BioPharma Group plc

    Cancer Ovaries

    phase 1 small molecule completed

    1 trial

  8. OMP-313M32

    Mereo BioPharma Group plc

    Locally Advanced Cancer

    phase 1 small molecule terminated

    1 trial

  9. OMP-336B11

    Mereo BioPharma Group plc

    Locally Advanced Malignant Neoplasm

    phase 1 small molecule terminated

    1 trial

  10. OMP-52M51

    Mereo BioPharma Group plc

    Relapsed or Refractory Solid Tumors

    phase 1 small molecule completed

    1 trial

  11. OMP-54F28

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 mab completed

    1 trial

  12. OMP-54F28 with Sorafenib

    Mereo BioPharma Group plc

    Hepatocellular Cancer

    phase 1 small molecule completed

    1 trial

  13. OMP-54F28, Nab-Paclitaxel and Gemcitabine

    Mereo BioPharma Group plc

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  14. OMP-54F28, Paclitaxel and Carboplatin

    Mereo BioPharma Group plc

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  15. OMP-59R5

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  16. OMTX705-001

    Lacuna Pharma Pty Ltd

    Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

    phase 1 other active

    1 trial

  17. OMTX705-006 Phase 1b

    Lacuna Pharma Pty Ltd

    Advanced/Metastatic Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

  18. ONC206

    Jazz Pharmaceuticals Ireland Limited

    Central Nervous System Neoplasms

    phase 1 small molecule active

    1 trial

  19. ONC206 Powder

    AXIM BIOTECHNOLOGIES, INC.

    Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

    phase 1 small molecule active

    1 trial

  20. ONO-4578

    Ono Pharmaceutical Co.,

    Metastatic Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  21. OP-3136

    Olema Pharmaceuticals

    Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)

    phase 1 small molecule active

    1 trial

  22. OPB-31121

    Otsuka Beijing Research Institute

    Non-Hodgkin's Lymphoma(NHL)

    phase 1 small molecule completed

    1 trial

  23. OPB-51602

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 1 small molecule terminated

    1 trial

  24. ORIC-101

    Topiloric/Uriadec

    Solid Tumor

    phase 1 small molecule terminated

    1 trial

  25. ORIC-101

    Topiloric/Uriadec

    Prostatic Neoplasms

    phase 1 small molecule terminated

    1 trial

  26. ORIC-114 Dose 1 + amivantamab

    Topiloric/Uriadec

    Solid Tumors

    phase 1 small molecule active

    1 trial

  27. ORIC-944

    Topiloric/Uriadec

    Metastatic Prostate Cancer

    phase 1 small molecule active

    1 trial

  28. Odronextamab

    Regeneron UK Limited

    B-cell Non-Hodgkins Lymphoma (B-NHL)

    phase 1 small molecule active

    1 trial

  29. Odronextamab multiple dose levels

    Regeneron UK Limited

    Non-Hodgkin Lymphoma

    phase 1 small molecule completed

    1 trial

  30. Olaparib tablets, 150 mg

    Sandoz Pty Ltd

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  31. Olutasidenib Investigational Agent Administration

    RIGEL PHARMACEUTICALS INC

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  32. Omacetaxine

    Teva Pharma GmbH

    Hematologic Tumors

    phase 1 small molecule completed

    1 trial

  33. Onartuzumab

    Hoffmann-La Roche

    Carcinoma, Hepatocellular

    phase 1 small molecule completed

    1 trial

  34. Oncolytic Virus SDJ001

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Tumor

    phase 1 small molecule active

    1 trial

  35. Optical PD-L1 imaging using Quantitative Fluo... for Esophageal cancer

    Disc Medicine

    Esophageal cancer

    phase 1 other active

    1 trial

  36. Osimertinib

    PUMA BIOTECHNOLOGY, INC.

    Lung Cancer Metastatic

    phase 1 small molecule active

    1 trial

  37. PAN-301-1

    Sensei Biotherapeutics

    Prostate Cancer

    phase 1 mab completed

    1 trial

  38. PARP inhibitor BMN-673

    BioMarin Pharmaceutical Australia Pty Ltd

    Metastatic Cancer

    phase 1 small molecule completed

    1 trial

  39. PB-2018-V12

    Chongqing Precision Biotech Co., Ltd

    Non-small Cell Lung Cancer

    phase 1 mab completed

    1 trial

  40. PCS6422 and capecitabine

    Processa Pharmaceuticals

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  41. PD-L1/IDO Peptide Vaccine

    IO Biotech

    High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

    phase 1 mab active

    1 trial

  42. PDR001

    Novartis Pharmaceuticals

    Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

    phase 1 mab completed

    1 trial

  43. PDR001

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  44. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Cholangiocarcinoma Non-resectable

    phase 1 small molecule terminated

    1 trial

  45. PEGPH20

    HALOZYME THERAPEUTICS, INC.

    Solid Tumor

    phase 1 small molecule completed

    2 trials

  46. PEGylated recombinant human hyaluronidase PH20

    HALOZYME THERAPEUTICS, INC.

    Non-small Cell Lung Cancer

    phase 1 small molecule terminated

    1 trial

  47. PERSEVERANCE EU

    CERO THERAPEUTICS HOLDINGS, INC.

    Non-Muscle-Invasive Bladder Cancer (NMIBC) refractory

    phase 1 other active

    1 trial

  48. PH-762

    Phio Pharmaceuticals

    Squamous Cell Carcinoma of the Skin

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.